We provide you with 20 years of free, institutional-grade data for JANX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of JANX. Explore the full financial landscape of JANX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-07 | 1817713 | JANX | 10-Q | Url |
| 2025-05-08 | 1817713 | JANX | 10-Q | Url |
| 2025-02-27 | 1817713 | JANX | 10-K | Url |
| 2024-11-06 | 1817713 | JANX | 10-Q | Url |
| 2024-08-07 | 1817713 | JANX | 10-Q | Url |
| 2024-05-08 | 1817713 | JANX | 10-Q | Url |
| 2024-03-08 | 1817713 | JANX | 10-K | Url |
| 2023-11-07 | 1817713 | JANX | 10-Q | Url |
| 2023-08-08 | 1817713 | JANX | 10-Q | Url |
| 2023-05-09 | 1817713 | JANX | 10-Q | Url |
| 2023-03-10 | 1817713 | JANX | 10-K | Url |
| 2022-11-10 | 1817713 | JANX | 10-Q | Url |
| 2022-08-09 | 1817713 | JANX | 10-Q | Url |
| 2022-05-10 | 1817713 | JANX | 10-Q | Url |
| 2022-03-18 | 1817713 | JANX | 10-K | Url |
| 2021-11-09 | 1817713 | JANX | 10-Q | Url |
| 2021-08-10 | 1817713 | JANX | 10-Q | Url |
| 2021-05-19 | 1817713 | JANX | S-1 | Url |
Janux Therapeutics(NASDAQ:JANX) 
Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering f...
Website: https://www.januxrx.com/
Founded: 2017
IPO Price: $17 (Jun 11, 2021)
CEO: David Campbell
Sector:
Industry:
Share this website to your friends
The information provided in this report about JANX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.